Table 6: Comparisons of thyroid hormones at any follow-up time-points in the second investigation.

Baseline
WK* treatment (54 cases)Sotalol treatment (54 cases)Control (55 cases) value ( value)**

FT3* (pmol/L)5.532 ± 2.3725.752 ± 2.6085.680 ± 2.4860.110 (0.896)
FT4* (pmol/L)18.469 ± 7.18219.351 ± 7.57719.046 ± 7.5760.195 (0.823)
TSH* (IU/mL)7.126 ± 10.4495.859 ± 8.6686.832 ± 10.1100.249 (0.780)

Three months
WK* treatment (54 cases)Sotalol treatment (54 cases)Control (55 cases) value ( value)**

FT3* (pmol/L)5.035 ± 0.9345.129 ± 0.9085.098 ± 0.9650.140 (0.870)
FT4* (pmol/L)15.664 ± 3.11216.061 ± 3.33615.994 ± 3.4650.222 (0.801)
TSH* (IU/mL)4.683 ± 4.2114.083 ± 3.4564.352 ± 3.8850.326 (0.722)

Six months
WK* treatment (54 cases)Sotalol treatment (54 cases)Control (55 cases) value ( value)**

FT3* (pmol/L)5.257 ± 0.9305.373 ± 0.9155.381 ± 1.0570.277 (0.758)
FT4* (pmol/L)16.446 ± 3.33916.916 ± 3.72716.955 ± 4.0140.317 (0.729)
TSH* (IU/mL)4.032 ± 3.4923.567 ± 2.8853.756 ± 3.2020.288 (0.750)

Nine months
WK* treatment (54 cases)Sotalol treatment (54 cases)Control (55 cases) value ( value)**

FT3* (pmol/L)5.367 ± 0.9755.458 ± 0.9585.590 ± 1.3280.566 (0.569)
FT4* (pmol/L)17.184 ± 3.20817.760 ± 4.13118.084 ± 4.8330.668 (0.514)
TSH* (IU/mL)2.912 ± 1.7302.701 ± 1.6662.785 ± 1.7190.211 (0.810)

Twelve months
WK* treatment (54 cases)Sotalol treatment (54 cases)Control (55 cases) value ( value)**

FT3* (pmol/L)5.562 ± 0.9695.740 ± 1.3025.874 ± 1.4060.866 (0.422)
FT4* (pmol/L)17.830 ± 3.48518.532 ± 5.11318.901 ± 5.3880.716 (0.490)
TSH* (IU/mL)2.519 ± 1.4202.388 ± 1.4232.409 ± 1.4880.129 (0.879)

WK: Wenxin Keli, FT3: free triiodothyronine, FT4: free thyroxine, and TSH: thyroid stimulating hormone; **analyzed by one-way analysis of variance and least significant difference test.